
|Videos|November 9, 2020
Endocrine Rundowns: Ertugliflozin and Renal Outcomes
Author(s)Patrick Campbell
A nephrologist and professor from the University of Toronto offers insight into the results of a key kidney outcomes analysis of the VERTIS-CV trial.
Advertisement
In this edition of Endocrine Rundowns, David Cherney, MD, PhD, an associate professor from University of Toronto, discussing a renal outcomes analysis of the VERTIS-CV trial, which was originally presented at EASD 2020. A relative newcomer to the SGLT2 inhibitor class, VERTIS-CV offers the first glimpse into the renal effects of ertugliflozin in patients. In the interview, Cherney, dives deeper into the results of the trial and also breaks down how the enrollment criteria compared to other outcomes trials examining use of SGLT2 inhibitors.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
Berobenatide Monthly Dosing Shows Weight Loss Efficacy in VESPER Trials, With John Buse, MD, PhD
4
What Comes Next for Berobenatide? VESPER-3 and Phase 3 Expectations, With John Buse, MD, PhD
5


























































